Predicting Lung Adenocarcinoma Prognosis with a Novel Risk Scoring Based on Platelet-related Gene Expression

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2021 Feb 23

PMID 33619234

Citations 8

Authors

Chengmao Zhou

Yongsheng Wang

Ying Wang

Lei Lei

Mu-Huo Ji

Guoren Zhou

Hongping Xia

Jian-Jun Yang

Affiliations

Soon will be listed here.

Abstract

Lung adenocarcinoma is the most common subtype of non-small cell lung cancer, and platelet receptor-related genes are related to its occurrence and progression. A new prognostic indicator based on platelet receptor-related genes was developed with multivariate COX analysis. Prognostic markers based on platelet-related risk score perform moderately in prognosis prediction. The functional annotation of this risk model in high-risk patients shows that the pathways related to cell cycle, glycolysis and platelet-derived related factors are rich. It is worth noting that somatic mutation analysis shows that TTN and MUC16 have higher mutation burdens in high-risk patients. Moreover, the differential genes of high- and low-risk groups are regulated by copy number variation and miRNA. And we provide a free online nomogram web tool based on clinical factors and the risk score (https://wsxzaq.shinyapps.io/wsxzaq_nomogram/). The score has been verified among three independent external cohorts (GSE13213, GSE68465 and GSE72094), and is still an independent risk factor for lung adenocarcinoma. In addition, among the other 6 cancers, the OS prognosis of high and low-risk groups of PRS is different (P < 0.05). Our research results have screened multiple platelet differential genes with clinical significance and constructed a meaningful prognostic risk score (PRS).

Citing Articles

Integrative multi-omics analysis for identifying novel therapeutic targets and predicting immunotherapy efficacy in lung adenocarcinoma.

Chen Z, Mei K, Tan F, Zhou Y, Du H, Wang M Cancer Drug Resist. 2025; 8:3.

PMID: 39935429 PMC: 11810459. DOI: 10.20517/cdr.2024.91.

A novel risk model consisting of nine platelet-related gene signatures for predicting prognosis, immune features and drug sensitivity in glioma.

Wei S, Zhou J, Dong B Hereditas. 2024; 161(1):52.

PMID: 39707577 PMC: 11662788. DOI: 10.1186/s41065-024-00355-7.

Characterization of platelet-related genes and constructing signature combined with immune-related genes for predicting outcomes and immunotherapy response in lung squamous cell carcinoma.

Zhao S, Gong H, Liang W Aging (Albany NY). 2023; 15(14):6969-6992.

PMID: 37477536 PMC: 10415560. DOI: 10.18632/aging.204886.

Characterization of Platelet Function-Related Gene Predicting Survival and Immunotherapy Efficacy in Gastric Cancer.

Xia Y, Lin X, Cheng Y, Xu H, Zeng J, Xie W Front Genet. 2022; 13:938796.

PMID: 35836573 PMC: 9274243. DOI: 10.3389/fgene.2022.938796.

Development of a Platelet-Related Prognostic Model for Colorectal Cancer.

Wang P, Zhao W, Cao H Front Genet. 2022; 13:904168.

PMID: 35719389 PMC: 9198283. DOI: 10.3389/fgene.2022.904168.

References

Zhou K, Yao Y, He Z, Chen C, Zhang X, Yang K . VDAC2 interacts with PFKP to regulate glucose metabolism and phenotypic reprogramming of glioma stem cells. Cell Death Dis. 2018; 9(10):988. PMC: 6155247. DOI: 10.1038/s41419-018-1015-x. View

Lien H, Lee Y, Jeng Y, Lin C, Lu Y, Yao Y . Differential expression of hyaluronan synthase 2 in breast carcinoma and its biological significance. Histopathology. 2014; 65(3):328-39. DOI: 10.1111/his.12390. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Zhang J, Zhang J, Yuan C, Luo Y, Li Y, Dai P . Establishment of the Prognostic Index Reflecting Tumor Immune Microenvironment of Lung Adenocarcinoma Based on Metabolism-Related Genes. J Cancer. 2020; 11(24):7101-7115. PMC: 7646164. DOI: 10.7150/jca.49266. View

Yang L, Jiang Q, Li D, Zhou X, Yu D, Zhong J . TIMP1 mRNA in tumor-educated platelets is diagnostic biomarker for colorectal cancer. Aging (Albany NY). 2019; 11(20):8998-9012. PMC: 6834400. DOI: 10.18632/aging.102366. View

Tsai W, Yu T, Lin L, Lin M, Wu Y, Liao C . Platelet rich plasma releasate promotes proliferation of skeletal muscle cells in association with upregulation of PCNA, cyclins and cyclin dependent kinases. Platelets. 2016; 28(5):491-497. DOI: 10.1080/09537104.2016.1227061. View

Kim D, Park S, Kim M, Ji Y, Kang M, Jung E . A functional single nucleotide polymorphism at the promoter region of cyclin A2 is associated with increased risk of colon, liver, and lung cancers. Cancer. 2011; 117(17):4080-91. DOI: 10.1002/cncr.25930. View

Samarghandian S, Azimi-Nezhad M, Farkhondeh T . Thymoquinone-induced antitumor and apoptosis in human lung adenocarcinoma cells. J Cell Physiol. 2018; 234(7):10421-10431. DOI: 10.1002/jcp.27710. View

Bongiovanni D, Santamaria G, Klug M, Santovito D, Felicetta A, Hristov M . Transcriptome Analysis of Reticulated Platelets Reveals a Prothrombotic Profile. Thromb Haemost. 2019; 119(11):1795-1806. DOI: 10.1055/s-0039-1695009. View

10.

Hendrix A, Maynard D, Pauwels P, Braems G, Denys H, Van den Broecke R . Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst. 2010; 102(12):866-80. PMC: 2886092. DOI: 10.1093/jnci/djq153. View

11.

Kang X, Kong F, Huang K, Li L, Li Z, Wang X . LncRNA MIR210HG promotes proliferation and invasion of non-small cell lung cancer by upregulating methylation of CACNA2D2 promoter via binding to DNMT1. Onco Targets Ther. 2019; 12:3779-3790. PMC: 6529604. DOI: 10.2147/OTT.S189468. View

12.

Song J, Im J, Nho R, Han Y, Upadhyaya P, Kassie F . Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells. Mol Carcinog. 2018; 58(3):321-333. PMC: 11005861. DOI: 10.1002/mc.22930. View

13.

Chen W . Cancer statistics: updated cancer burden in China. Chin J Cancer Res. 2015; 27(1):1. PMC: 4329178. DOI: 10.3978/j.issn.1000-9604.2015.02.07. View

14.

Li J, Ying Y, Xie H, Jin K, Yan H, Wang S . Dual regulatory role of CCNA2 in modulating CDK6 and MET-mediated cell-cycle pathway and EMT progression is blocked by miR-381-3p in bladder cancer. FASEB J. 2018; 33(1):1374-1388. DOI: 10.1096/fj.201800667R. View

15.

Wang F, Li L, Zhang Z . Platelet isoform of phosphofructokinase promotes aerobic glycolysis and the progression of non‑small cell lung cancer. Mol Med Rep. 2020; 23(1). PMC: 7716410. DOI: 10.3892/mmr.2020.11712. View

16.

Pelikant-Malecka I, Sielicka A, Kaniewska E, Smolenski R, Slominska E . Influence of 4-pyridone-3-carboxamide-1Β-D-ribonucleoside (4PYR) on activities of extracellular enzymes in endothelial human cells. Nucleosides Nucleotides Nucleic Acids. 2016; 35(10-12):732-736. DOI: 10.1080/15257770.2016.1174263. View

17.

Zhou C, Wang Y, Lei L, Ji M, Yang J, Xia H . Identifying Common Genes Related to Platelet and Immunity for Lung Adenocarcinoma Prognosis Prediction. Front Mol Biosci. 2020; 7:563142. PMC: 7658298. DOI: 10.3389/fmolb.2020.563142. View

18.

Chiu D, Tse A, Xu I, Cui J, Lai R, Li L . Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nat Commun. 2017; 8(1):517. PMC: 5593860. DOI: 10.1038/s41467-017-00530-7. View

19.

Hekmat O, Munk S, Fogh L, Yadav R, Francavilla C, Horn H . TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells. J Proteome Res. 2013; 12(9):4136-51. DOI: 10.1021/pr400457u. View

20.

Menter D, Tucker S, Kopetz S, Sood A, Crissman J, Honn K . Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev. 2014; 33(1):231-69. PMC: 4186918. DOI: 10.1007/s10555-014-9498-0. View